Article | July 21, 2020

4 Ways To Avoid COA Source Revisions And Mitigate Risk In Your Global Clinical Trials

Source: TransPerfect

By Rebecca Weatherholtz, Director, TransPerfect Life Sciences Solutions

Cell phone clinical trial patient form COA

When an English source requires a revision after translations have begun, this can be a major challenge in maintaining set budgets and timelines in global COA clinical trials. Often, these revisions seem minor but can end up having a significant impact on the multiple languages in scope for a study. An often-overlooked aspect of source revisions is that in addition to increasing timelines and costs, they also add inherent risk to the quality of the translations. While source revisions cannot be completely avoided, there are ways to prevent many of them that will greatly increase the probability of a successful launch.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader